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Abstract. Especially in the area of genomics, global research institutions 
constantly provide new insights. Yet today we lack insight on how the use of 
research data in clinical practice is facilitated. Our study researches an 
entrepreneurial venture as complementing actor in the international health 
context who bridges data use from research to science. In this paper, we present 
a three-step framework how the venture legitimizes data-driven services to 
facilitate research data use in clinical practice. Our findings illustrate that the 
venture managed to adjust to clinical needs by using three mechanisms: 1) 
assessing and aggregating, 2) allowing for ambiguity and 3) assuring clinical 
assistance. This study adds to the understanding of new ventures’ services 
legitimation scaling across traditionally national healthcare with local systems. 
Moreover, our framework is of interest to entrepreneurs and investors, who seek 
entrepreneurial opportunities and information about ventures that have been able 
to navigate this field. 
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1 Introduction 
Genome data and genetic medicine have promising global advancements such as 
personalized medicine, new diagnostic methods and new disease treatment that are of 
relevance to humankind [1–3]. Genetics is a field that benefits greatly from the 
digitalization of research data. Borders between research and application are blurring 
in genetics, because the ongoing research efforts have direct relevance in healthcare 
practice [4]. It is thus becoming increasingly relevant to integrate highly international 
and research-centered efforts into local (national) medical practice [5]. This is not an 
easy task, as scientific research and healthcare institutions currently work separately 
from each other, pursue different goals and use different information systems [6]. 
Information systems (IS) researchers have pointed out these challenge and the need to 
include the field of genetics to advance IS research [7–9].  
How to use the ubiquity of (research) data? That is a relevant question, it has only 
played a minor role in health IS research which has often discussed national projects in 
context of national healthcare. We follow an earlier research call to explore how 
research flows into clinical applications [5] and show the novel possibilities that 
entrepreneurial ventures can take in healthcare [10], serving new and complex needs of 
various stakeholder groups. 
We are especially interested in new venture-provided services in biological, 
specifically human genome data [11, 12]. Our study researches a data-intensive, young 
firm (entrepreneurial venture) as a complementing actor in international health services 
[9, 13]. Our research question is: How can a third-party venture legitimize new data 
services to facilitate research data use in healthcare? In our empirical case study, we 
explore a venture that supports sharing and generating insights between international 
researchers and healthcare practitioners. We explain how the venture establishes new 
services for a heterogeneous range of stakeholders.  
2 Background  
2.1 From Traditionally Local to International Context of Healthcare  
In today’s IS health literature, the “durability and central role of existing practices, 
conventions, tools and systems” [14] is often central to studying the challenges along 
the lifecycle of building, adapting and evolving local health systems and information 
infrastructure in national healthcare [15–18]. Healthcare research seldom refers to 
international projects that establish or adapt healthcare related services with digital 
technology. The focus on a siloed setup in local healthcare settings ties traditional 
healthcare research to addressing challenges with a rather localized view [15, 19–21]. 
But comparably new and recent fields for medical treatment rely on cross-institutional 
and cross-national collaboration and data exchange [22, 23]. 
Data-related problems impact healthcare sector globally: Western countries as well 
as developing countries experience difficulties in ensuring that data are standardized 
[24] are safely shared [21, 25], available [26] and lead to legitimate services [20, 27]. 
For analysis in clinical diagnosis, the representation of health-related problems in data 
is paramount: In data-heavy fields like genomics, access to these data and the need for 
sharing initiatives are the desired path to advance clinical practice [2, 4, 28, 29]. Little 
standardization exists, and large datasets grow incessantly [30–32]. The shift of 
attention from local healthcare concerns to global communities is appropriate as data 
digitization is transforming healthcare [24, 33, 34] as it removes limitations of physical 
access while also “dissolv[ing] product and industry boundaries” [35].  
2.2 The Role of Data in Clinical and Research Context 
Today, healthcare and research institutions are working with different stakeholder 
groups. Healthcare institutions involve distinct stakeholders—patients, insurance 
companies and medical practitioners—relying on the existing prevalent clinical 
problems and proven diagnostic guidelines [15, 17, 18]. In contrast, research institutes 
take up risks to find methods, diseases and cures that are unknown to date and explore 
large sets of new data in collaborative and country-spanning programs [6, 36]. Indeed, 
researchers have often distinguished between clinical institutions (healthcare, as in 
hospital or care institutions) [14, 18, 19] and research institutions [37–39]. This 
separation conveys the impression that they are not connected, yet as mentioned in the 
previous chapter, data is the blood that runs both in the veins of research and healthcare 
institutions [30, 40, 41]. Thus, we do not believe that the division of discovery and 
application to different kinds of organizations is the best way to approach this issue 
[21]. Surprisingly, data as a resource is only infrequently discussed in health IS 
literature on research and clinical institutions. Scientific institutions could not directly 
care for the data (re)use in healthcare [6], and while international patients exchange 
forums (Patients Like Me) are rather common by now [42], we know little about the 
involvement of clinicians and researchers in such areas. We think the assumptions 
behind this rather limited view of health-related matters should be challenged [5]. Data 
are the basis for both of these activities (research and clinical) and should be focused 
on [29, 33, 37, 43]. 
2.3 The Role of Third Parties in Serving New Healthcare Needs  
As digitization and data sharing across countries facilitate the collaboration of 
multiple organizations, third parties can also take a role in previously less digitized 
fields such as healthcare [11, 44, 45]. A third-party firm as incumbent might act as an 
intermediary, as the involvement of third-party firms has several interesting benefits to 
healthcare:  
First, with digital services, the venture is likely to aim for growth of its user base 
[46, 47] and establish a proposition to fit more than one organization. If successful, the 
complexity of adapting to the broad range of healthcare stakeholders could be avoided, 
and healthcare would be freed from the burden of deeply local IS transformation 
projects [13, 17, 21].  Meanwhile, it could have a greater effect—that is, reach more 
communities in healthcare overall. Second, ventures seek to establish new services and 
innovative solutions [48] and might compensate for limitations that existing healthcare 
institutions would have been hindered from overcoming once principles for their local 
IS systems are defined [14]. Third, while digital technology ventures have an interest 
in quickly appropriating value from their work and achieve growth [46, 49, 50], they 
also seek legitimacy from existing structures [51, 52]: experimenting and probing with 
the right standards of digitized data and technology in a strictly regulated field, can be 
applied with existing procedures that are key to healthcare organizations, too [52–54]. 
Within the realms of entrepreneurial ventures in other sectors, we find different 
strategies used to navigate in such new markets [54], but in healthcare, we know little 
about how such industry-spanning ventures bring different requirements together. 
2.4 The Context of Genomic Health  
In healthcare, all diseases are somehow mirrored in genetic components, and 
knowledge regarding genetic pathology is constantly growing [3]. Technological 
progress has lowered the cost of genome sequencing over time, and an increasing 
number of healthcare practitioners now use genetic data for diagnostics [44, 55].  
Research institutions have access to large scalable infrastructure for use in basic 
research because sharing, collaborative problem solving and open experimentation are 
crucial for scientists when tackling complex questions [37]. The existing IS systems in 
research are tuned toward processing large amounts of data to find new patterns. Data 
governance and quality in the related science repositories are not necessarily suitable 
for healthcare organizations [7]. Healthcare institutions need data from research to 
verify their findings [56, 57]. They may risk ignoring new knowledge or over- or 
underestimating the impact of their findings by finding other, similar cases [58, 59]. A 
genetic diagnosis that has not been validated primarily affects patients who run the risk 
of receiving an inaccurate diagnosis, living with uncured pain, or succumbing to death. 
Reference systems could be provided eventually, but would be general in purpose; 
establishing those will take years to come [23]. The activity of firms that prepare data 
and offer their exclusive services for commercial fees [7, 29] is not beneficial for 
countries that have little means to afford such access. However, the interest in 
simultaneous research and diagnostic use has increase the interest in entrepreneurial 
ventures in health [9, 13]. 
3 Case Description 
Our case investigates an entrepreneurial venture in Switzerland that leverages openly 
available scientific data to support the intersection of research and healthcare practice. 
Established in 2013, the company provides services to over 200’000 users across the 
globe, namely Asia, North and South America and Europe. The case company vision 
is to create a genome data service for various interest groups with most essential 
information on genetic variants and their documentation, annotation, connection and 
classification. Users can access all services online via a web-based search application 
that leverages data pre-processed primarily from research sources, including more than 
50 internationally acknowledged data repositories. These include RefSeq, ClinVar 
(National Center for Biological Information), gnomAD with more than 120 single 
investigators and contributing projects, and numerous additional data sources. The 
venture runs its service across 33 billion data points. 
4 Methodology 
Our goal is to provide explanations [60] that allow a better understanding of research  
data use in healthcare, second, for the role of entrepreneurial ventures in gaining 
legitimacy to establish the respective services to facilitate the data use. Thus, an in-
depth understanding of the phenomenon requires us to consider multiple sources and 
means of data collection, as well as a long preparation phase in which we understand 
the context of the science, healthcare and genome data infrastructure. We present an 
unusual and revelatory case in health IS that is best understood using an embedded case 
study [61]. The uniqueness of our case shows in distinctive attributes, compared to 
other small ventures.  First, there is the market success of this venture. It has enjoyed a 
two-digit growth rate in the last five years and has reached by now over 200’000 users. 
These users come from over 120 countries and underline that the venture’s services 
address global needs. In this study, we expect to observe the factors that resulted in the 
venture’s legitimacy, as the. We understand that the opposing needs and settings of 
science’s and healthcare’s data use are complex to address. In contrast to other 
entrepreneurial ventures that operate either for healthcare or science, our case company 
refers to both worlds and bridges a gap that is hardly visible in previous papers. This 
has been confirmed once we had talked to users, who refer to this venture’s services as 
their main reference points. Finally, the venture has a pioneering status due to its 
comprehensiveness for over 50 data sources from different data sources and ease of 
use.  
Having gathered extensive background knowledge from the industry, we observed 
the firm as a first unit of analysis for 2 years and included the users as a second unit of 
analysis. Hence, we exclude with relative certainty the possibility that “the issues that 
motivate our study are (sometimes) stated as imaginary pseudo-problems” [62].  
4.1 Data Collection 
The interview data were collected during semi-structured interviews, which were 
held in English. The questionnaire for the first round of interviews focused on the role 
of the employees (all in the leadership team), their motivation, and the description of 
the product and its function, users, as well as their relationship to research institutions 
and clinical institutions. Review meetings were held to confirm that the information 
collected was still valid as stated in the interviews and to ensure that users could be 
contacted. From 100 requests to users, 5 users signaled their willingness to participate 
in interview. These users were asked about their role, the module and actual use of the 
product and what they had used as a solution before they found it. All audio interviews 
were recorded and transcribed.  
  
Table 1. Data Collection 






Seminars on human genome 
diagnosis; shadowing 









product demos, roundtable 
with IS researchers in health 
in three countries 




Interview with CEO, 10/18  70 m. Rec. 
Interview with CTO, 02/19  30 m. Rec. 
Interview with PM, 02/19  45 m. Rec. 
Update with CEO, 04/19 30 m. Notes 
Update with Product 
manager, 12/19 
20 m. Notes  
Users 01-
03/2020 
Interviews with current users 
(MDs, researchers) of the 
firm’s services in Mexico, 
France, Turkey, Spain and 
Iran  




4.2 Data Analysis 
The analysis of all material was performed with MaxQDA. Applying inductive 
principles of Gioia [63], we created a rich set of codes, resulting in a pattern and a set 
of 1st order themes close to the informants’ expressions. Though iterative literature and 
data analysis, higher-level, 2nd order themes were created. Finally, aggregated 
dimensions helped us explain how new services were created and legitimized by the 
ventures.  Findings were also discussed with two non-authoring researchers. 
5 Findings 
Figure 1. Findings of Venture’s Mechanisms 
We present our findings referring to the 1st order concepts and proceed with the 
explanation of the aggregated dimensions in the next chapter. 
5.1 Establishing Common Ground 
The firm downloads the data from research repositories and processes all data in 
their proprietary physical servers in Switzerland. This data dump is then transformed 
to fit one database model with consolidated metadata (handled in what is like a mapping 
of different databases). This requires disambiguation, transformation of formats and 
cleansing of data. The firm stores the data and the associated meaning, including 
comments and relationships, in separated structures for faster retrieval of the required 
data in context of the command entered by users. Disease prediction mechanisms are 
applied and re-calculated daily, based on the insights from single databases. 
(a) One of the classic problems whenever you deal with sequences in biology each 
database has its own identifier. So, the same gene can be known in at least 20 different 
ways. (…) So, we will have tables that combine this information to allow me to go from 
ensemble transcript identifier to a the equivalent refseq identifier. That is a data 
process that we will set up. (…) That tells me where the gene is located, the start 
position the end position the exomes et cetera were found. literally an own table in the 
MySQL database. So, what we will add is the table that links the different identifiers 
that helps us communicate between the different data sources and databases. (PM) 
The service provides a threshold by which it shows disambiguated results for a 
disease-causing meaning of the variant, in addition the variant meaning is classified 
with an applied standard by American College of Medical Genetics (ACMG) for 
healthcare. All services in their Product (Product A) access the two structures but 
returns depending on the services. The CEO would not want to interfere with the 
domain knowledge of genetics. Instead, they engage with stakeholders of the platforms 
like ClinVar to ensure their offering is adjusted to a common understanding of the 
“industry standard”. Based on the industry understanding and new tools being created, 
the users (often medical doctors, but also researchers at the same time) would see the 
firm provided updates in the service to do justice to new best practices in the 
community. All available data and analysis tools in the web interface include 
relationships to classification for healthcare, clinical meaning and various other 
attributes. Once the results were returned, there appeared numerous options for a drill 
down and exploration, which always returned the respective associated knowledge 
from different sources. The new information first went to the interface for researchers 
and free users: That interface was free to access, the firm uses it to test and validate 
new functions, standards it had imported and data it loaded. 
 (b,c) It gives the – prediction average of 21 prediction tools. It makes an average. 
And I already, I trust its rather than a mutation tester (…) because revel includes an 
average prediction. So, I am very pleased to see Product A to include it in recent 
months. (User from Turkey) 
5.2 Encouraging Global Contributions from Researchers and Clinicians 
When users access the services, they do not only see the result and a visualization of 
the attached meaning (variant finding related information for example from a specific 
ethnographic group, publication on the variant, suggestions for variant-associated 
diseases, prediction tools for the variant effects…). The user would also be able to 
common on the finding with own contributions. In fact, finding comments of other 
medical professionals or researchers would be useful to verify the retrieved information 
and also correct the data where meaning (classification = pp is pathogenic, disease 
causing) could be put into context. That is important to know, because users would 
come from various backgrounds and the meaning of a variant in, say, leukemia would 
be different from a variant that is researched related to kidney cancer. Also, phenomena 
that span the globe could be identified and shared, as a user (researcher and medical 
doctor) from Mexico explained. 
 (e) I have seen that others, other people in other laboratories, many Asian, they 
have seen some of our variants that we classified, I guess they are seeing them or they 
are recommending them also because that is a linked with their patients and our 
patients in this variants of uncertain significance.  (User from Mexico) 
This effect was carefully deployed by the venture due to its supporting effect for 
both quality and legitimacy in the community. A researcher who found others’ 
comments (mostly also with a short note on the affiliation and background of the 
individual) would allow them to see which legitimation it had in eyes of other 
researchers of similar or other disciplines. Both firm and users explained us that the 
free services are “tuned” towards a reinforcement of clinical use – to both encourage 
contribution and to avoid too much free riding. Once the limitation of 100 free searches 
is consumed, the firm requests users to contribute back to the community with a 
classification of a variant. While the user is not forced to contribute, the firm leverages 
the implication (speed decreases) to encourage the user to contribute.  
(f) It actually helps a lot because all the feedback we get from the community helps 
us make it better. Especially as I said when there is a lot of room for interpretation of 
any data. We launched it here first. We get feedback from a thousand people let's say. 
It's of course a variant quality and we have to use our judgement to see who is liked 
and who is most likely to be more reputable. (CEO) 
 
The set-up of the services considers possibilities of discovery, with is relevant where 
new insights appear (so called “de novo” findings, with little experience and data to 
refer to). The community was required to assess and contribute, either in the sources 
that the firm pulls in, or in the actual service interface to converse about the clarification 
and generation of new knowledge. For established findings on variants with associated 
diseases, the services encouraged refinement and re-use of knowledge which exists in 
various existing platforms through their commenting function and daily loads of new 
information. A user from France who faced a very rare condition in a patient was able 
to contact the respective user who had contributed to the classification of the candidate 
gene, who then allowed him to achieve a confirmation of the phenotype and diagnosis.  
 
(g) So today, we’ve been able to identify a new candidate gene, thanks to Product A, 
another variant which was disturbing because, the phenotype was quite severe and did 
not know if the variant was really pathogenic. And Product A was really useful to 
connect to the patient with the same variant (User from France) 
 
In addition, we found that the researcher and medical community included less 
privileged participants. Being deprived of other possibilities, the user from Iran 
regarded the possibility to collaborate via webservice as a unique opportunity to share 
his knowledge and benefit from a wider range of contributors he would otherwise not 
have access to.  
 
 (h) Users can see my classification and it’s easy for them to decide if a variant that 
they identified is pathogenic or not. I always try to do this, because I think it’s helpful 
for others. But we are underdeveloped country, it is very hard for us to manage or 
design a system to help people. People in the country, but you as a developed country 
it’s easy for you, you can collaborate all around the world. (User from Iran) 
5.3 Accounting for Distinct Clinical Requirements  
Another service that the firm offered was specifically built for clinical use in 
diagnosis, it also had to be In Vitro Diagnostics (IVD) certified and was only available 
for a fee. This service serves as an extension to diagnostic analysis for doctors who had 
an entire patient sequence available. The firm checked for personal data attributes 
(names, address, etc.) and would delete such attributes if contained. The genome then 
could – only with one click- be annotated (show the different assessments and degrees 
of pathogenic variants, the associations with diseases and reference data from various 
sources). Then, the venture had ensured that the user would receive a snapshot which 
annotations at the time of the upload and annotation. As the knowledge of the human 
genome still progresses, the user needs a justification that he used the knowledge 
available at the time.  
 
(l) This is an advanced clinical platform. For example, it contains pictures such as 
audit trails. In other words, it tracks your uses of the platform in case there's ever any 
legal issue. (..) On Product A here, we keep updating the data. Here we keep updating 
the data for new analysis of new patients. If you have analyzed a patient the data is 
frozen exactly to the state of the day of the analysis, so that there's no issue afterwards. 
The knowledge that was available on that day allowed us to produce this report. You 
can also create a diagnostic report. (CEO) 
6 Results and Discussion 
Our study looks at a venture that uses more than 50 large genetic research sources to 
facilitate its use in a medical context. We find that the third party uses three mechanisms 
to legitimize their services [64]: 1) assessing and assigning weight, 2) allowing for 
ambiguity and assertion, and 3) assuring clinical assistance. These mechanisms are 
prerequisites that must be fulfilled for the venture to legitimize these data services. The 
venture applies them sequentially (1, 2, 3) and independently in order to successfully 
achieve legitimacy. We describe them in more detail. 
6.1 Assessing and Assigning Weight  
The venture represents itself as a partner to organizations to reduce uncertainty and 
provide support in standard-setting. In lack of one standard, they consolidate standards 
to apply with hand-selected, curated and processed data sources, which reduces also the 
uncertainty for the venture: A combined reference may be a factor enhancing timeliness 
and disambiguation as more contributions – also contradicting ones- are included [8, 
65]. In overcoming the rigidity of a one-standard-system that would hold data in a local 
healthcare infrastructure, the venture as arbitrator separates the data itself from the 
context they are used in (literally saving them in different places) and shows data even 
when there are contradicting insights that come from various groups (example: from a 
rather breast-cancer-focused database from research, applying a data standard that 
mostly clinicians use). Data silos are a problem which is well known in clinical context, 
the low transparency of the related silos producing data [21, 66] is mitigated with this 
third party involvement. Leveraging known standards in their innovation of IS [67, 68] 
they can ensure a reference point of “known” trusted settings from clinical settings and 
at the same time keep generativity of data high [24].  
6.2 Allowing for Ambiguity and Assertion 
The users of the venture’s services also work at the intersection of the institution 
types (as researchers and laboratory workers for clinical labs, or as medical doctors who 
pursue research interests, too). For the venture, research and practice are just as closely 
intertwined as genetics [5, 69]: This ambiguity of roles is acknowledged as the data can 
be enriched with new interpretations. In a dynamic field as genetics where new data 
and classification are added [70] the venture can only prove its legitimation of the 
service when it allows references to be established by its users who are discovering and 
using the data themselves in various settings [45, 52]. The online exchange on the 
venture’s webservice are openly and globally accessible and allow of diverging 
opinions, uncertainties and connections like a non-medical or non-professional online 
forum  [15, 33, 71]. That also provides a non-threatening context to clinicians and 
researchers, where they are not judged.  
6.3 Assuring Clinical Assistance 
Finally, the clinical service of the venture seeks to transfer physical medical 
standards to digital processes. The In Vitro Diagnostics (IVD) certified procedure, for 
which also humans have the responsibility in the end. Attaching evidence of the 
references used (data sources, annotated reports and justification documents for data 
used) it is closest to the procedure clinicians know [52]. Task-related procedures instead 
of fully integrated systems could support also from external providers. Activities of 
such complexity, split into modules as the venture does, then, would only lead to small 
transformations that do not affect existing healthcare information systems [14].  
 
In sum, that brings a totally new perspective to healthcare research, moving away 
from additions to the local healthcare practice to cross-border service that can fit into 
any healthcare system. Thus, the legitimation of new services can scale across sectors 
and countries. Instead of holding one person right away accountable for a comment, the 
venture promotes easy access for exchange [72]. The peer validation and feedback 
mechanisms remind us of the open source movement. The meaning of different findings 
is discussed and validated in the context of each user. That context can be very different 
and diverse, but with global contributions, weighs more [73]. Local healthcare 
information systems are much less flexible [8, 14]. There, a change project for installed 
base systems is likely to span years and would be unlikely to generate such scale as 
they work local, are locally regulated and have a limited set of data, too [14, 21]. 
 
 
7 Conclusion  
Within a dynamic and data-rich environment, where research and clinical borders 
blur, third parties can add to the healthcare landscape by offering new services. In our 
study, we observed a venture that addresses both research and healthcare stakeholders, 
who usually find themselves working in segregated systems without touchpoints. We 
find that the venture brings stakeholders from both sides together via their new services. 
The case shows that different mechanisms of legitimation are enabled through digital 
technology through mirroring what has been considered a relevant reference (e.g. 
framework, certification) in clinical practice. Moreover, as the three mechanisms work 
independently from established national healthcare systems but greatly enhance the 
work of clinicians, we see these as modular elements that can scale legitimation of new 
services. With these contributions, we call for more research on the role of ventures as 
intermediaries within healthcare in a dynamic and complex field such as genetics. 
 
Our findings have clear limitations. In our single case study, we reveal first 
mechanisms that help us understand how a venture uses technology, both scientific and 
healthcare communities and established certifications to legitimate its services. More 
research on other organizations increases the external credibility of our findings; 
focusing on a single case by necessity leads into questions about transferability of 
findings to other cases. As our findings may not apply to all ventures, we add three 
boundary conditions that describe how to identify “similar” cases. We hope they help 
guide other researchers on how to determine the applicability of our findings [74]: 
- (1) Use of technology is appropriate and configured by one or more 
stakeholders (decide how it should be done)  
- (2) Involvement of communities is feasible and allowed (to delegate the 
legitimation mechanisms in part to others)  
- (3) The necessity of validation and achieve legitimacy is open to a range of 
legitimacy values (in our study: either clinical, scientific exploration etc.) 
 
If one of these prerequisites is not met, the degree of legitimation we have shown in 
our study needs to be re-assessed. However, we see no reason to not to believe that the 
mechanisms identified in this single case study would be dramatically different in other 
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